TWI859508B - 骨骼疾病治療用醫藥組成物 - Google Patents
骨骼疾病治療用醫藥組成物 Download PDFInfo
- Publication number
- TWI859508B TWI859508B TW111105929A TW111105929A TWI859508B TW I859508 B TWI859508 B TW I859508B TW 111105929 A TW111105929 A TW 111105929A TW 111105929 A TW111105929 A TW 111105929A TW I859508 B TWI859508 B TW I859508B
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- mesenchymal stem
- stem cells
- cell
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 208000020084 Bone disease Diseases 0.000 title claims description 14
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 88
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims abstract description 16
- 210000000963 osteoblast Anatomy 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 148
- 210000001185 bone marrow Anatomy 0.000 claims description 29
- 206010049933 Hypophosphatasia Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 101150052863 THY1 gene Proteins 0.000 claims description 15
- 206010010356 Congenital anomaly Diseases 0.000 claims description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 46
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 35
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 35
- 238000002054 transplantation Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- 210000000988 bone and bone Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940108347 strensiq Drugs 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 230000011164 ossification Effects 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101150014183 Alpl gene Proteins 0.000 description 6
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 210000003074 dental pulp Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000046949 human MSC Human genes 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000020470 nervous system symptom Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000003599 Larsen syndrome Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 1
- 208000033128 Multiple osteochondromas Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000003567 TRPV4 Human genes 0.000 description 1
- 101150098315 TRPV4 gene Proteins 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000009854 congenital contractural arachnodactyly Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000010903 hereditary multiple osteochondromas Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 208000034277 severe hypophosphatasia Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021024794 | 2021-02-19 | ||
| JP2021-024794 | 2021-02-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202302123A TW202302123A (zh) | 2023-01-16 |
| TWI859508B true TWI859508B (zh) | 2024-10-21 |
Family
ID=82930724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111105929A TWI859508B (zh) | 2021-02-19 | 2022-02-18 | 骨骼疾病治療用醫藥組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240316109A1 (https=) |
| JP (1) | JP7636032B2 (https=) |
| KR (1) | KR20230133892A (https=) |
| AU (1) | AU2022222868B2 (https=) |
| CA (1) | CA3211195A1 (https=) |
| TW (1) | TWI859508B (https=) |
| WO (1) | WO2022177032A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015043768A (ja) * | 2013-08-02 | 2015-03-12 | 有未 伊谷 | ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び／または品質評価を行う方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6363950U (https=) | 1986-06-17 | 1988-04-27 | ||
| WO2016017795A1 (ja) | 2014-08-01 | 2016-02-04 | 有未 伊谷 | ヒト間葉系幹細胞の品質評価方法、及び、そのためのモノクローナル抗体 |
| WO2021144995A1 (ja) * | 2020-01-16 | 2021-07-22 | ＰｕＲＥＣ株式会社 | 高純度間葉系幹細胞 |
-
2022
- 2022-02-18 WO PCT/JP2022/008103 patent/WO2022177032A1/ja not_active Ceased
- 2022-02-18 CA CA3211195A patent/CA3211195A1/en active Pending
- 2022-02-18 JP JP2023500979A patent/JP7636032B2/ja active Active
- 2022-02-18 KR KR1020237028336A patent/KR20230133892A/ko active Pending
- 2022-02-18 US US18/277,618 patent/US20240316109A1/en active Pending
- 2022-02-18 TW TW111105929A patent/TWI859508B/zh active
- 2022-02-18 AU AU2022222868A patent/AU2022222868B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015043768A (ja) * | 2013-08-02 | 2015-03-12 | 有未 伊谷 | ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び／または品質評価を行う方法 |
Non-Patent Citations (2)
| Title |
|---|
| 期刊 Mabuchi et al. LNGFR+THY-1+VCAM-1hi+ Cells Reveal Functionally Distinct Subpopulations in Mesenchymal Stem Cells Stem Cell Reports 1(2) 2013 152-165 |
| 期刊 Taketani et al. Ex Vivo Expanded Allogeneic Mesenchymal Stem Cells With Bone Marrow Transplantation Improved Osteogenesis in Infants With Severe Hypophosphatasia Cell Transplantation 24 2015 1931-1943;期刊 Mabuchi et al. LNGFR+THY-1+VCAM-1hi+ Cells Reveal Functionally Distinct Subpopulations in Mesenchymal Stem Cells Stem Cell Reports 1(2) 2013 152-165 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230133892A (ko) | 2023-09-19 |
| JP7636032B2 (ja) | 2025-02-26 |
| AU2022222868A1 (en) | 2023-09-07 |
| CA3211195A1 (en) | 2022-08-25 |
| JPWO2022177032A1 (https=) | 2022-08-25 |
| US20240316109A1 (en) | 2024-09-26 |
| WO2022177032A1 (ja) | 2022-08-25 |
| TW202302123A (zh) | 2023-01-16 |
| AU2022222868B2 (en) | 2026-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meyerrose et al. | Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors | |
| US8986744B2 (en) | Stem cell populations and methods of use | |
| KR100973615B1 (ko) | 산후 포유류의 태반, 이의 용도 및 태반 줄기세포 | |
| CN101848991A (zh) | 分离的细胞群 | |
| JP2001518289A (ja) | 多分化能神経幹細胞からの造血細胞の生成 | |
| KR20170010894A (ko) | 림프구로부터의 다계열 분화능 세포 생성 방법 | |
| CN112912087A (zh) | 线粒体向淋巴器官中的移植以及用于该移植的组合物 | |
| US20230014549A1 (en) | Mesenchymal stem cells for use in the treatment of chronic kidney disease | |
| US20230012590A1 (en) | Mesenchymal stem cells for use in the treatment of chronic gingivostomatitis | |
| TWI859508B (zh) | 骨骼疾病治療用醫藥組成物 | |
| CN103585179A (zh) | 一种药物组合物及其在制备治疗骨髓造血功能障碍疾病的药物中的应用 | |
| US20150353897A1 (en) | Method of generating multilineage potential cells | |
| KR20240034745A (ko) | 동물의 골관절염 치료용 중간엽 줄기세포 | |
| JP7003283B2 (ja) | 末梢血から間葉系幹細胞集団を製造する方法及びその使用 | |
| Filip et al. | Homing of lin−/CD117+ hematopoietic stem cells | |
| Ruan et al. | Different hematopoietic reconstruction abilities of transplanted cells from bone marrow, spleen, liver and peripheral blood | |
| TW202529782A (zh) | 含有高純度間葉系幹細胞之用以治療以及／或是預防粒線體疾病之組成物 | |
| AU2024354572A1 (en) | Composition for treating and/or preventing mitochondrial disease including high-purity mesenchymal stem cells | |
| Grainger | Haemopoietic Allogenic Stem Cell Transplantation, With Co-Infusion of Mesenchymal Stem Cells, in a Transplant Model of Hurler Syndrome | |
| KR20140021156A (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 신경계 질환 치료용 약학적 조성물 | |
| KR20140127187A (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 신경계 질환 치료용 약학적 조성물 | |
| KR20140021153A (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 면역관련 질환 치료용 약학적 조성물 |